ATE505485T1 - Appetithemmendes peptid, zusammensetzung und verwendung - Google Patents

Appetithemmendes peptid, zusammensetzung und verwendung

Info

Publication number
ATE505485T1
ATE505485T1 AT08103786T AT08103786T ATE505485T1 AT E505485 T1 ATE505485 T1 AT E505485T1 AT 08103786 T AT08103786 T AT 08103786T AT 08103786 T AT08103786 T AT 08103786T AT E505485 T1 ATE505485 T1 AT E505485T1
Authority
AT
Austria
Prior art keywords
peptide
composition
appetitive
absent
formula
Prior art date
Application number
AT08103786T
Other languages
German (de)
English (en)
Inventor
Lars Thim
Birgitte Wulff
Martin Judge
Ole Madsen
Jens Holst
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE505485(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE505485T1 publication Critical patent/ATE505485T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT08103786T 1996-03-01 1997-02-27 Appetithemmendes peptid, zusammensetzung und verwendung ATE505485T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK23096 1996-03-01
DK23196 1996-03-01

Publications (1)

Publication Number Publication Date
ATE505485T1 true ATE505485T1 (de) 2011-04-15

Family

ID=26063575

Family Applications (3)

Application Number Title Priority Date Filing Date
AT08103786T ATE505485T1 (de) 1996-03-01 1997-02-27 Appetithemmendes peptid, zusammensetzung und verwendung
AT97905000T ATE227737T1 (de) 1996-03-01 1997-02-27 Gebrauch einer pharmazeutischen zusammensetzung, enthaltend ein appetitzügelndes peptid
AT01122701T ATE395359T1 (de) 1996-03-01 1997-02-27 Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT97905000T ATE227737T1 (de) 1996-03-01 1997-02-27 Gebrauch einer pharmazeutischen zusammensetzung, enthaltend ein appetitzügelndes peptid
AT01122701T ATE395359T1 (de) 1996-03-01 1997-02-27 Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung

Country Status (22)

Country Link
EP (4) EP1231218B1 (OSRAM)
JP (1) JP4064460B2 (OSRAM)
KR (1) KR100611130B1 (OSRAM)
CN (1) CN1112367C (OSRAM)
AT (3) ATE505485T1 (OSRAM)
AU (1) AU710818B2 (OSRAM)
BR (1) BR9707807A (OSRAM)
CA (1) CA2246733C (OSRAM)
CY (2) CY2619B2 (OSRAM)
CZ (1) CZ297338B6 (OSRAM)
DE (3) DE69738695D1 (OSRAM)
DK (2) DK1975177T3 (OSRAM)
ES (3) ES2306685T3 (OSRAM)
FR (1) FR13C0009I2 (OSRAM)
HU (1) HU229234B1 (OSRAM)
IL (1) IL125805A0 (OSRAM)
NO (2) NO323043B1 (OSRAM)
PL (1) PL187095B1 (OSRAM)
PT (1) PT1975177E (OSRAM)
RU (1) RU2197261C2 (OSRAM)
UA (1) UA70283C2 (OSRAM)
WO (1) WO1997031943A1 (OSRAM)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
HU229234B1 (en) * 1996-03-01 2013-09-30 Novo Nordisk As Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DK1231219T3 (da) 1996-04-12 2010-12-20 Ontario Inc 1149336 GLucagon-lignende peptid-2 analoger
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP2001504105A (ja) * 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１ペプチドの利用
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
ES2222613T3 (es) * 1997-09-12 2005-02-01 Pharis Biotec Gmbh Composicion para la terapia de diabetes mellitus y de la obesidad.
EP1049486A4 (en) * 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
EP1060192A2 (en) * 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002506792A (ja) * 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
AU3087599A (en) * 1998-03-19 1999-10-11 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
EP2067488A1 (en) 2000-04-12 2009-06-10 Human Genome Sciences, Inc. Albumin fusion proteins
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
DE60134251D1 (de) * 2000-09-18 2008-07-10 Sanos Bioscience As Verwendung von glp-2-peptiden
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
EP1346722B1 (en) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
DE602004031927D1 (de) 2003-02-04 2011-05-05 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
DE602004031455D1 (de) 2003-12-09 2011-03-31 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1-agonisten
WO2005070468A2 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
JP5030292B2 (ja) 2004-04-15 2012-09-19 アミリン・ファーマシューティカルズ，インコーポレイテッド ポリマーを基にした持続放出性装置
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
RU2262945C1 (ru) * 2004-04-29 2005-10-27 Закрытое акционерное общество "Научно-производственное предприятие "Тринита" Способ снижения массы тела в эксперименте на животных
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EA014184B1 (ru) 2005-05-04 2010-10-29 Зеаланд Фарма А/С Аналоги глюкагонподобного пептида-2 (glp-2)
DE602005017628D1 (de) 2005-09-22 2009-12-24 Biocompatibles Uk Ltd Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送系统和活塞组件
KR101527233B1 (ko) 2006-11-08 2015-06-08 질랜드 파마 에이/에스 선택적인 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
DK2157967T3 (da) 2007-04-23 2013-04-08 Intarcia Therapeutics Inc Suspensionsformuleringer af insulinotropiske peptider og anvendelser deraf
US20100278843A1 (en) * 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9453064B2 (en) 2012-05-03 2016-09-27 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
BR112019010624A2 (pt) 2016-12-09 2019-10-22 Zealand Pharma As agonistas duplos de glp-1/glp-2 acilados e composição
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
DK3881861T3 (da) 2017-06-16 2024-09-09 Zealand Pharma As Doseringsregimer for indgivelse af glukagonlignende peptid-2- (GLP-2)-analoger
EP3966224A4 (en) * 2019-05-06 2023-08-23 The University of Sydney PROTEIN FRACTIONATION METHODS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
JP2523562B2 (ja) 1985-10-25 1996-08-14 ザイモジェネティックス インコーポレーテッド 外来タンパク質を分泌することを目的としたｂａｒ１の使用法
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
WO1989001029A1 (en) 1987-07-24 1989-02-09 Cetus Corporation Airlift insect cell culture
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO1990005783A1 (en) 1988-11-18 1990-05-31 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
HU229234B1 (en) * 1996-03-01 2013-09-30 Novo Nordisk As Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Also Published As

Publication number Publication date
EP1231218A3 (en) 2002-10-30
EP1975177B1 (en) 2011-04-13
ATE227737T1 (de) 2002-11-15
CN1112367C (zh) 2003-06-25
NO2013006I1 (no) 2013-04-02
NO2013006I2 (OSRAM) 2013-03-12
CA2246733C (en) 2010-07-20
EP0891378B1 (en) 2002-11-13
CY2619B2 (OSRAM) 2013-03-13
WO1997031943A1 (en) 1997-09-04
DK0891378T3 (da) 2003-01-06
DE69717092D1 (de) 2002-12-19
FR13C0009I1 (OSRAM) 2013-03-22
HUP9902670A3 (en) 2000-02-28
AU710818B2 (en) 1999-09-30
DE69740176D1 (de) 2011-05-26
NO984005L (no) 1998-08-31
ATE395359T1 (de) 2008-05-15
CY2013008I2 (el) 2015-08-05
PT1975177E (pt) 2011-07-26
EP0891378A1 (en) 1999-01-20
DK1975177T3 (da) 2011-07-25
CN1215405A (zh) 1999-04-28
KR19990087439A (ko) 1999-12-27
JP4064460B2 (ja) 2008-03-19
CZ273698A3 (cs) 1998-12-16
AU1871597A (en) 1997-09-16
CZ297338B6 (cs) 2006-11-15
JP2000505460A (ja) 2000-05-09
EP1231218B1 (en) 2008-05-14
PL187095B1 (pl) 2004-05-31
EP1231218A2 (en) 2002-08-14
DE69738695D1 (de) 2008-06-26
HU229234B1 (en) 2013-09-30
ES2364705T3 (es) 2011-09-12
UA70283C2 (en) 2004-10-15
EP2295453A3 (en) 2011-03-30
ES2306685T3 (es) 2008-11-16
BR9707807A (pt) 1999-07-27
PL328732A1 (en) 1999-02-15
KR100611130B1 (ko) 2006-11-30
RU2197261C2 (ru) 2003-01-27
EP1975177A1 (en) 2008-10-01
ES2187756T3 (es) 2003-06-16
NO323043B1 (no) 2006-12-27
DE69717092T2 (de) 2003-07-24
IL125805A0 (en) 1999-04-11
CY2013008I1 (el) 2015-08-05
NO984005D0 (no) 1998-08-31
FR13C0009I2 (fr) 2013-08-16
CA2246733A1 (en) 1997-09-04
EP2295453A2 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
ATE505485T1 (de) Appetithemmendes peptid, zusammensetzung und verwendung
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
ATE289517T1 (de) Verwendung von glp-1 peptiden
NO992557D0 (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
DK1171465T3 (da) Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
DE60143234D1 (de) Peptid
DK0759772T3 (da) Tri-, tetra-, penta- og polypeptider og deres terapeutiske anvendelse som antidepressiva
MX9601655A (es) Proteinas (ob) obesas recombinantes.
DE69927524D1 (de) Topoisomerase-ii inhibitoren
GB9614191D0 (en) Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1975177

Country of ref document: EP